Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News TNF Pharmaceuticals Inc TNFA

TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a... see more

Recent & Breaking News (NDAQ:TNFA)

SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.

PR Newswire November 12, 2020

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akers Biosciences, Inc. (NASDAQ:AKER)

ACCESSWIRE IA November 12, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.

PR Newswire November 12, 2020

Akers Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Akers Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - AKER

Business Wire November 12, 2020

Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement

Business Wire November 12, 2020

Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results

GlobeNewswire August 27, 2020

Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire August 11, 2020

Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies

GlobeNewswire July 7, 2020

Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire May 18, 2020

Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire May 14, 2020

Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP

GlobeNewswire May 14, 2020

Here's How Akers Biosciences and Premas Biotech Plan To Knock Out COVID-19 Virus; Company Halfway Through Four Milestone Plan

Newsfile April 24, 2020

Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens

GlobeNewswire April 8, 2020

Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire April 7, 2020

Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

GlobeNewswire April 6, 2020

Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate

GlobeNewswire March 24, 2020

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

GlobeNewswire March 24, 2020

Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation

GlobeNewswire January 17, 2020

Akers BioSciences Regains Compliance with Nasdaq Listing Standards

GlobeNewswire December 11, 2019

Akers Biosciences to Present at the Investor Summit on December 17th in Philadelphia

Accesswire December 10, 2019